First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggests

(MedPage Today) -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy for older patients with previously untreated advanced non-small cell lung cancer (NSCLC) provided no survival advantage compared with ICI therapy alone, according to...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news